Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
- Conditions
- SARS VirusSARS-CoV-2COVID-19
- Interventions
- Other: PlaceboOther: Convalescent SARS COVID-19 plasma
- Registration Number
- NCT04383535
- Lead Sponsor
- Hospital Italiano de Buenos Aires
- Brief Summary
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of clinical status at day 30 after study initiation.
- Detailed Description
Introduction
The use of convalescent plasma in the treatment of infectious diseases has been empirically performed for more than a century. It is based upon the assumption that providing exogenous neutralizing antibodies may provide protection while affected patients mount their own immune response. This therapeutic approach appears of particular interest in the context of the current pandemic, in which there is no specific vaccine available nor adequately proven effective pharmacological treatments.
Study purpose, hypothesis and general design
Purpose of the study: evaluate the effectiveness and safety of convalescent plasma in the treatment of SARS-CoV-2 pneumonia (Covid-19) Hypothesis: Convalescent plasma significantly improves the clinical outcome in patients with Covid-19 pneumonia and severity criteria.
Multicenter randomized, double-blind, placebo.controlled clinical trial. Placebo will be a saline solution.
3. Methodological sustain for including a control arm with placebo Quality evidence about the effectiveness of convalescent plasma in the treatment of Covid-19 pneumonia is not yet available. Although case series and anecdotal reports appear encouraging, the implementation of its use in routine clinical practice requires the validation through controlled clinical trials. In addition the collection, administration and control of plasma is technically demanding and needs a clear support before broadly recommending it. Different scientific institutions and international organisms had clearly suggested to prioritize the application of novel therapeutic techniques with yet unproven efficacy within the context of clinical studies over its empirical use.
On the other hand, for the present study, intervention strategy is proposed in "add-on" modality over the antiviral treatment that each participant may be already receiving, since they represent completely different therapeutic approaches. As such, participation in the present study will not condition the possibility of the participants to receive other treatments, either in intervention or control arms.
4. Study objectives Primary objective Analyze the difference between arms on an ordinal score of six mutually exclusive categories at day 30 after study initiation. This score includes the following categories
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 333
- Confirmed diagnosis of Covid-19 through qualitative polymerase-reverse transcriptase (qRT-PCR -GeneDX Co, Ltd o similar).
- Imagining-diagnosed pneumonia (Rx or CT scan).
- MSOFA score (Modified SOFA) of 2 or more (modified organic failure assessment)
- Informed consent.
- Pregnant women
- Women at reproductive age not willing to avoid unprotected sexual intercourse up to Day 30 after study initiation.
- Women in the breastfeeding period
- Patients receiving experimental treatments under development within 30 days prior to study initiation.
- Patients with a previous history of allergic reactions to blood or blood-components transfusion.
- Diagnosis or clinical suspicion of an alternative microbiological cause for pneumonia besides COVID-19
- Use of systemic corticosteroids within 15 days prior to entering the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Single infusion of saline solution, in addition to standard care. Convalescent SARS COVID-19 plasma Convalescent SARS COVID-19 plasma Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma, in addition to standard care.
- Primary Outcome Measures
Name Time Method Clinical status during follow-up at 30th day 30th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Ordinal outcome with six mutually exclusive categories to describe the patient's clinical status during follow-up. The six categories are: (1) death; (2) in intensive care; (3) hospitalised but requiring supplemental oxygen; (4) hospitalised and not requiring supplemental oxygen; (5) discharged but unable to resume normal activities; or (6) discharged with full resumption of normal activities.
- Secondary Outcome Measures
Name Time Method Time to death In a 30 days follow up period Death and time to death
Clinical status during follow-up at 7th day 7th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Ordinal outcome with six mutually exclusive categories to describe the patient's clinical status during follow-up. The six categories are: (1) death; (2) in intensive care; (3) hospitalised but requiring supplemental oxygen; (4) hospitalised and not requiring supplemental oxygen; (5) discharged but unable to resume normal activities; or (6) discharged with full resumption of normal activities.
Time until discharge from ICU (days) Whenever the patient is discharge from ICU or die in ICU, through study completion, an average of 10 days from admission ICU discharge or ICU death
Time until hospital discharge (days). Whenever the patient is discharge from the hospital or die without discharge, through study completion, an average of 14 days from admission Hospital discharge or intrahospital death
Plasma concentration of neutralizing antibodies at Day 7th 7th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Plasma concentration of neutralizing antibodies
Time until complete functional recovery Whenever the patient returns to basal functional status until 1 month from discharge Time until complete functional recovery (according to basal status).
Percentage of patients with negative SARS-CoV-3 PCR at Day 14th 14th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Percentage of patients with negative SARS-CoV-3 PCR
D Dimer plasma concentration at Day 14th 14th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) D Dimer plasma concentration
Ferritin plasma concentration at Day 13th 13th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Ferritin plasma concentration
Clinical status during follow-up at 14th day 14th Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Ordinal outcome with six mutually exclusive categories to describe the patient's clinical status during follow-up. The six categories are: (1) death; (2) in intensive care; (3) hospitalised but requiring supplemental oxygen; (4) hospitalised and not requiring supplemental oxygen; (5) discharged but unable to resume normal activities; or (6) discharged with full resumption of normal activities.
Percentage of participants with adverse events / serious adverse events In a 30 days follow up period Percentage of participants with adverse events / serious adverse events
Post-transfusion adverse reactions In a 30 days follow up period Post-transfusion adverse reactions between study groups
Plasma concentration of neutralizing antibodies at Day 2nd 2nd Day since study preparation infusion (Placebo or Convalescent SARS COVID-19 plasma) Plasma concentration of neutralizing antibodies
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hospital Italiano de Buenos Aires
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina